Sign in
Taking peopleNo phase

Efficacy of Electroacupuncture for Acute Herpes Zoster-Associated Pain and Biomarker Evaluation

Key facts

Who runs it
Dexiong Han
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
228 people, planned
Started
1 Sept 2025
Expected to end
31 Dec 2028
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Acupuncture
  • Sham
  • Valacyclovir, pregabalin and mecobalamin
Record updated
16 June 2026

Who can take part

Age
20 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (12)Hide the full registry criteria

Who can take part

  • Patients who meet the diagnostic criteria for acute HZ27 and skin symptom appears less than 7 days
  • Only have lesions in the trunk and limbs
  • Patients with a Numerical Rating Scale (NRS) score ≥ 4; 3. Aged between 20 and 80 years; 4. Patients voluntarily participate in the trial and are willing to sign the informed consent

Who cannot take part

  • Has received relevant treatment and it may affect the observation indicators
  • Those who are afraid of acupuncture or have metal implants and are not suitable for EA treatment
  • Special types of HZ that occur in head, eyes, viscera, etc. or those combined with other skin diseases
  • Patients who are allergic to iodophor or other topical disinfectants, or a history of sudden, potentially life-threatening systemic allergic reactions
  • Those with contraindications to pregabalin such as congestive heart disease and heart failure
  • Patients with severe primary diseases such as liver, kidney, cardiovascular and cerebrovascular, metabolic, autoimmune system diseases, malignant tumors, etc., and those with mental illness
  • Patients who have hematologic diseases or coagulation disorders
  • Pregnant and lactating women
  • Patients who are currently participating in other clinical studies

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Acute herpes zoster

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Background: Herpes zoster (HZ) is an acute dermatological condition caused by the varicella-zoster virus. Its onset is characterized by severe pain, imposing significant physical and psychological burdens on patients. Acupuncture offers distinct advantages in treating acute herpes zoster and associated pain. However, the therapeutic efficacy of electroacupuncture for acute herpes zoster, its potential to reduce PHN incidence, and the role of biomarkers in predicting PHN incidence require further clinical validation.

Read full original descriptionShow less

Methods: A total of 228 patients with acute herpes zoster will be recruited from 3 hospitals and randomly assigned to EA group or medication-alone group or sham acupuncture group in a 1:1:1 ratio, utilizing multicenter stratified block randomization. The trial will involve a 2 week treatment period, and a 3-month follow-up period. All variables will be evaluated at week 0, week 1, week 2, and on the 90th day after rash onset. All participants will continue antiviral medication treatment. Primary outcome is Numerical Rating Scale; secondary outcomes include herpes lesion crusting time, pain episodes within a 24-hour period, Hamilton Anxiety Scale, Hamilton Depression Scale, 36-Item Short Form Health Survey, changes of biomarkers (Erythrocyte sedimentation rate, C-reactive protein, Tumor Necrosis Factor-α, Interleukin-10, Substance P and neuropeptide Y) and PHN incidence rate. All adverse effects will be assessed during the trial.

Conclusion: This study will elucidate the efficacy of electroacupuncture in treating acute herpes zoster, whether electroacupuncture can reduce the incidence of PHN, and the role of biomarkers in predicting the incidence of PHN.

The 3 groups in the trial

  • Electroacupuncture groupTreatment being tested

    Treatment: Acupuncture and Valacyclovir, pregabalin and mecobalamin

  • sham acupuncture groupPlacebo, for comparison

    Treatment: Sham and Valacyclovir, pregabalin and mecobalamin

  • Medication-Alone GroupPlacebo, for comparison

    Treatment: Valacyclovir, pregabalin and mecobalamin

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Research on the Therapeutic Effect of Electroacupuncture on Acute Herpes Zoster-Associated Pain and Its Anti-inflammatory Injury Mechanism
Criteria questions
Built from NCT07515885, who can take part
Record updated
16 June 2026